Download Library



Download Library
Document Type
2017 Responsibility Report
Download Center
view presentation
2018 Financial Overview Presentation
Cemiplimab Commercialization-Related Accounting: Illustratve Example Presentation
View Presentation
View Presentation
Safety and preliminary clinical activity of REGN1979, an anti-CD20 × anti-CD3 bispecific antibody, in patients with B-NHL previously treated with CD20-directed antibody therapy
Safety and Preliminary Antitumor Activity of the Anti-PD-1 Monoclonal Antibody Cemiplimab (REGN2810) Alone or in Combination with REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with B-Lymphoid Malignancies
View Presentation
Presentations - Featured Presentation
= add file to Briefcase